Colleen C. Mccormick
Experienced in Cervical Cancer

Dr. Colleen C. Mccormick

Obstetrics and Gynecology | Oncology
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, 
Baltimore, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Experienced in Cervical Cancer
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Colleen McCormick, M.D., M.P.H., is an assistant professor in the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine in Baltimore. Her areas of clinical expertise include gynecologic oncology with a focus on cervical and endometrial cancers, complex cancer cases and surgery for gynecologic cancers. A Baltimore native, Dr. McCormick received her undergraduate degree from Earlham College in Richmond, Virginia. Her advanced degrees include a doctorate in medicine and a Master of Public Health from Johns Hopkins. Dr. McCormick completed her residency as well as the F.J. Montz Fellowship in Gynecologic Oncology at The Johns Hopkins Hospital. She has significant clinical experience, initially in Portland, Oregon, where she was the medical director at Legacy Gynecologic Oncology. She was most recently at the University of New Mexico before returning home to Johns Hopkins and Baltimore. Her research interests include clinical trial programs, focusing on increasing diversity and inclusion in clinical trials. Deeply invested in patient experience, she recently served as a patient safety officer at the University of New Mexico, and she has researched practitioner and patient perspectives regarding endometrial cancer care. She has additional training in palliative care and genetic counseling, and she strongly values being able to accompany patients through their entire cancer journey. Dr. McCormick is a published author and has been invited to lecture both regionally and nationally.

Dr. Mccormick is rated as an Experienced provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Ovarian Carcinosarcoma, and Bladder Reconstruction.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Cervical Cancer.

Graduate Institution
Johns Hopkins Bloomberg School Of Public Health, Public Health, MPH, 2007
Residency
Johns Hopkins University School of Medicine, Obstetrics & Gynecology, 2006
Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in OR
Board Certifications
American Board Of Obstetrics And Gynecology
Fellowships
Johns Hopkins University School of Medicine, Gynecologic Oncology, 2009
Hospital Affiliations
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 6, Floor 6, Baltimore, MD 21287
Call: 410-955-8240
Other Locations
Johns Hopkins Medicine Gynecology & Obstetrics - Eldersburg
5961 Exchange Drive, Suite 108, Eldersburg, MD 21784
Call: 410-955-8240

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Paclitaxel, Ruxolitinib phosphate
Study Phase: Phase 1/Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
View 13 Less Clinical Trials
Similar Doctors
Leslie M. Randall
Elite in Cervical Cancer
Dr. Leslie M. Randall
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Cervical Cancer
Dr. Leslie M. Randall
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Capital Womens Care LLC

46179 Westlake Dr, 
Potomac Falls, VA 
 (47.0 miles away)
703-430-7770
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leslie Randall is a Gynecologic Oncologist and an Oncologist in Potomac Falls, Virginia. Dr. Randall is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Hysterectomy. Dr. Randall is currently accepting new patients.

Stephanie Gaillard
Distinguished in Cervical Cancer
Dr. Stephanie Gaillard
Oncology
Distinguished in Cervical Cancer
Dr. Stephanie Gaillard
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 10th FL, Viragh BLDG 10th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, French
See accepted insurances
Offers Telehealth

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies. Dr. Gaillard is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy.

Distinguished in Cervical Cancer
Dr. Lori Cory
Oncology
Distinguished in Cervical Cancer
Dr. Lori Cory
Oncology

LG Health Physicians Gynecologic Oncology

2102 Harrisburg Pike, 
Lancaster, PA 
 (54.7 miles away)
717-544-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lori Cory is an Oncologist in Lancaster, Pennsylvania. Dr. Cory is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Hysterectomy, and Lymphadenectomy. Dr. Cory is currently accepting new patients.

VIEW MORE CERVICAL CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccormick's expertise for a condition
ConditionClose
    • Distinguished
    • Ovarian Cancer
      Dr. Mccormick is
      Distinguished
      . Learn about Ovarian Cancer.
      See more Ovarian Cancer experts
    • Advanced
    • Endometrial Cancer
      Dr. Mccormick is
      Advanced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Endometrial Stromal Sarcoma
      Dr. Mccormick is
      Advanced
      . Learn about Endometrial Stromal Sarcoma.
      See more Endometrial Stromal Sarcoma experts
    • Malignant Mixed Mullerian Tumor
      Dr. Mccormick is
      Advanced
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Ovarian Carcinosarcoma
      Dr. Mccormick is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Sertoli-Leydig Cell Tumor
      Dr. Mccormick is
      Advanced
      . Learn about Sertoli-Leydig Cell Tumor.
      See more Sertoli-Leydig Cell Tumor experts
    • Testicular Yolk Sac Tumor
      Dr. Mccormick is
      Advanced
      . Learn about Testicular Yolk Sac Tumor.
      See more Testicular Yolk Sac Tumor experts
    View All 9 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Mccormick is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Bladder Reconstruction
      Dr. Mccormick is
      Experienced
      . Learn about Bladder Reconstruction.
      See more Bladder Reconstruction experts
    • Cervical Cancer
      Dr. Mccormick is
      Experienced
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Cervical Dysplasia
      Dr. Mccormick is
      Experienced
      . Learn about Cervical Dysplasia.
      See more Cervical Dysplasia experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Mccormick is
      Experienced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Eccrine Porocarcinoma
      Dr. Mccormick is
      Experienced
      . Learn about Eccrine Porocarcinoma.
      See more Eccrine Porocarcinoma experts
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.